PUMA BIOTECHNOLOGY, INC. Research and Development Expense
PUMA BIOTECHNOLOGY, INC. (PBYI) reported Research and Development Expense of $11.97 million for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-08-04.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2022-08-04
- PUMA BIOTECHNOLOGY, INC. research and development expense for the quarter ending 2022-06-30 was $11.97M, a 35.80% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. research and development expense for the quarter ending 2022-03-31 was $15.24M, a 24.67% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. research and development expense for the quarter ending 2021-12-31 was $14.17M, a 41.36% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. research and development expense for the quarter ending 2021-09-30 was $18.84M, a 19.31% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. research and development expense for fiscal 2021 was $71.87M, a 26.40% decline from fiscal 2020.
- PUMA BIOTECHNOLOGY, INC. research and development expense for fiscal 2020 was $97.65M, a 26.50% decline from fiscal 2019.
- PUMA BIOTECHNOLOGY, INC. research and development expense for fiscal 2019 was $132.85M, a 19.41% decline from fiscal 2018.
- PUMA BIOTECHNOLOGY, INC. research and development expense for fiscal 2018 was $164.85M, a 20.67% decline from fiscal 2017.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed | Research and Development Expense 16 month | Research and Development Expense 18 month | Research and Development Expense 21 month | Research and Development Expense 25 month | Research and Development Expense 27 month | Research and Development Expense 30 month | Research and Development Expense 33 month | Research and Development Expense 36 month | Research and Development Expense 39 month | Research and Development Expense 42 month | Research and Development Expense 45 month | Research and Development Expense 48 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-06-30 | $11.97M 10-Q · filed 2022-08-04 | $27.20M 10-Q · filed 2022-08-04 | $41.37M derived: sum of 3 quarters · filed 2022-08-04 | $60.21M derived: sum of 4 quarters · filed 2022-08-04 | ||||||||||||||||
| 2022-03-31 | $15.24M 10-Q · filed 2022-05-05 | $29.41M derived: sum of 2 quarters · filed 2022-05-05 | $48.24M derived: sum of 3 quarters · filed 2022-05-05 | $66.88M derived: sum of 4 quarters · filed 2022-08-04 | ||||||||||||||||
| 2021-12-31 | $14.17M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $33.00M derived: sum of 2 quarters · filed 2022-03-03 | $51.64M derived: sum of 3 quarters · filed 2022-08-04 | $71.87M 10-K · filed 2022-03-03 | ||||||||||||||||
| 2021-09-30 | $18.84M 10-Q · filed 2021-11-04 | $37.47M derived: sum of 2 quarters · filed 2022-08-04 | $57.70M 10-Q · filed 2021-11-04 | $81.86M derived: sum of 4 quarters · filed 2022-08-04 | ||||||||||||||||
| 2021-06-30 | $18.64M 10-Q · filed 2022-08-04 | $38.87M 10-Q · filed 2022-08-04 | $63.03M derived: sum of 3 quarters · filed 2022-08-04 | $86.37M derived: sum of 4 quarters · filed 2022-08-04 | ||||||||||||||||
| 2021-03-31 | $20.23M 10-Q · filed 2022-05-05 | $44.39M derived: sum of 2 quarters · filed 2022-05-05 | $67.73M derived: sum of 3 quarters · filed 2022-05-05 | $92.42M derived: sum of 4 quarters · filed 2022-05-05 | ||||||||||||||||
| 2020-12-31 | $24.16M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $47.50M derived: sum of 2 quarters · filed 2022-03-03 | $72.19M derived: sum of 3 quarters · filed 2022-03-03 | $97.65M 10-K · filed 2022-03-03 | ||||||||||||||||
| 2020-09-30 | $23.34M 10-Q · filed 2021-11-04 | $48.03M derived: sum of 2 quarters · filed 2021-11-04 | $73.49M 10-Q · filed 2021-11-04 | $103.73M derived: sum of 4 quarters · filed 2022-03-03 | ||||||||||||||||
| 2020-06-30 | $24.69M 10-Q · filed 2021-08-05 | $50.15M 10-Q · filed 2021-08-05 | $80.39M derived: sum of 3 quarters · filed 2022-03-03 | $110.41M derived: sum of 4 quarters · filed 2022-03-03 | ||||||||||||||||
| 2020-03-31 | $25.45M 10-Q · filed 2021-05-06 | $55.70M derived: sum of 2 quarters · filed 2022-03-03 | $85.72M derived: sum of 3 quarters · filed 2022-03-03 | $122.58M derived: sum of 4 quarters · filed 2022-03-03 | ||||||||||||||||
| 2019-12-31 | $30.24M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $60.27M derived: sum of 2 quarters · filed 2022-03-03 | $97.12M derived: sum of 3 quarters · filed 2022-03-03 | $132.85M 10-K · filed 2022-03-03 | ||||||||||||||||
| 2019-09-30 | $30.03M 10-Q · filed 2020-11-05 | $66.88M derived: sum of 2 quarters · filed 2020-11-05 | $102.61M 10-Q · filed 2020-11-05 | $140.94M derived: sum of 4 quarters · filed 2021-03-01 | ||||||||||||||||
| 2019-06-30 | $36.85M 10-Q · filed 2020-08-06 | $72.58M 10-Q · filed 2020-08-06 | $110.91M derived: sum of 3 quarters · filed 2021-03-01 | $147.27M derived: sum of 4 quarters · filed 2021-03-01 | ||||||||||||||||
| 2019-03-31 | $35.73M 10-Q · filed 2020-05-07 | $74.05M derived: sum of 2 quarters · filed 2021-03-01 | $110.41M derived: sum of 3 quarters · filed 2021-03-01 | $153.66M derived: sum of 4 quarters · filed 2021-03-01 | ||||||||||||||||
| 2018-12-31 | $38.33M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $74.69M derived: sum of 2 quarters · filed 2021-03-01 | $117.93M derived: sum of 3 quarters · filed 2021-03-01 | $164.85M 10-K · filed 2021-03-01 | ||||||||||||||||
| 2018-09-30 | $36.36M 10-Q · filed 2019-11-07 | $79.61M derived: sum of 2 quarters · filed 2019-11-07 | $126.53M 10-Q · filed 2019-11-07 | $176.78M derived: sum of 4 quarters · filed 2020-02-28 | ||||||||||||||||
| 2018-06-30 | $43.24M 10-Q · filed 2019-08-09 | $90.17M 10-Q · filed 2019-08-09 | $140.42M derived: sum of 3 quarters · filed 2020-02-28 | $189.93M derived: sum of 4 quarters · filed 2020-02-28 | ||||||||||||||||
| 2018-03-31 | $46.92M 10-Q · filed 2019-05-10 | $97.18M derived: sum of 2 quarters · filed 2020-02-28 | $146.68M derived: sum of 3 quarters · filed 2020-02-28 | $199.93M derived: sum of 4 quarters · filed 2020-02-28 | ||||||||||||||||
| 2017-12-31 | $50.25M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $99.76M derived: sum of 2 quarters · filed 2020-02-28 | $153.01M derived: sum of 3 quarters · filed 2020-02-28 | $207.81M 10-K · filed 2020-02-28 | ||||||||||||||||
| 2017-09-30 | $49.50M 10-Q · filed 2018-11-05 | $102.75M derived: sum of 2 quarters · filed 2018-11-05 | $157.56M 10-Q · filed 2018-11-05 | $213.95M derived: sum of 4 quarters · filed 2019-03-01 | ||||||||||||||||
| 2017-06-30 | $53.25M 10-Q · filed 2018-08-09 | $108.05M 10-Q · filed 2018-08-09 | $164.45M derived: sum of 3 quarters · filed 2019-03-01 | $216.43M derived: sum of 4 quarters · filed 2019-03-01 | ||||||||||||||||
| 2017-03-31 | $54.80M 10-Q · filed 2018-05-10 | $111.20M derived: sum of 2 quarters · filed 2019-03-01 | $163.18M derived: sum of 3 quarters · filed 2019-03-01 | $217.39M derived: sum of 4 quarters · filed 2019-03-01 | ||||||||||||||||
| 2016-12-31 | $56.40M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $108.38M derived: sum of 2 quarters · filed 2019-03-01 | $162.59M derived: sum of 3 quarters · filed 2019-03-01 | $222.80M 10-K · filed 2019-03-01 | ||||||||||||||||
| 2016-09-30 | $51.98M 10-Q · filed 2017-11-09 | $106.19M derived: sum of 2 quarters · filed 2017-11-09 | $166.40M 10-Q · filed 2017-11-09 | $218.84M derived: sum of 4 quarters · filed 2018-03-09 | ||||||||||||||||
| 2016-06-30 | $54.22M 10-Q · filed 2017-08-09 | $114.42M 10-Q · filed 2017-08-09 | $166.86M derived: sum of 3 quarters · filed 2018-03-09 | $218.79M derived: sum of 4 quarters · filed 2018-03-09 | ||||||||||||||||
| 2016-03-31 | $60.21M 10-Q · filed 2017-05-10 | $112.65M derived: sum of 2 quarters · filed 2018-03-09 | $164.57M derived: sum of 3 quarters · filed 2018-03-09 | $223.95M derived: sum of 4 quarters · filed 2018-03-09 | ||||||||||||||||
| 2015-12-31 | $52.44M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | $104.36M derived: sum of 2 quarters · filed 2018-03-09 | $163.74M derived: sum of 3 quarters · filed 2018-03-09 | $208.47M 10-K · filed 2018-03-09 | ||||||||||||||||
| 2015-09-30 | $51.92M 10-Q · filed 2016-11-09 | $111.31M derived: sum of 2 quarters · filed 2016-11-09 | $156.03M 10-Q · filed 2016-11-09 | $195.56M derived: sum of 4 quarters · filed 2017-03-01 | ||||||||||||||||
| 2015-06-30 | $59.38M 10-Q · filed 2016-08-09 | $104.11M 10-Q · filed 2016-08-09 | $143.64M derived: sum of 3 quarters · filed 2017-03-01 | $175.73M derived: sum of 4 quarters · filed 2017-03-01 | ||||||||||||||||
| 2015-03-31 | $44.73M 10-Q · filed 2016-05-10 | $84.26M derived: sum of 2 quarters · filed 2017-03-01 | $116.35M derived: sum of 3 quarters · filed 2017-03-01 | $151.35M derived: sum of 4 quarters · filed 2017-03-01 | ||||||||||||||||
| 2014-12-31 | $39.53M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $71.62M derived: sum of 2 quarters · filed 2017-03-01 | $106.62M derived: sum of 3 quarters · filed 2017-03-01 | $122.92M 10-K · filed 2017-03-01 | ||||||||||||||||
| 2014-09-30 | $32.09M 10-Q · filed 2015-11-09 | $67.09M derived: sum of 2 quarters · filed 2015-11-09 | $83.39M 10-Q · filed 2015-11-09 | $96.39M derived: sum of 4 quarters · filed 2016-02-29 | $178.90M 10-Q · filed 2014-11-10 | |||||||||||||||
| 2014-06-30 | $35.00M 10-Q · filed 2015-08-10 | $51.30M 10-Q · filed 2015-08-10 | $64.30M derived: sum of 3 quarters · filed 2016-02-29 | $76.37M derived: sum of 4 quarters · filed 2016-02-29 | $146.80M 10-Q · filed 2014-08-11 | |||||||||||||||
| 2014-03-31 | $16.29M 10-Q · filed 2015-05-11 | $29.30M derived: sum of 2 quarters · filed 2016-02-29 | $41.37M derived: sum of 3 quarters · filed 2016-02-29 | $51.81M derived: sum of 4 quarters · filed 2016-02-29 | $111.80M 10-Q · filed 2014-05-12 | |||||||||||||||
| 2013-12-31 | $13.01M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $25.07M derived: sum of 2 quarters · filed 2016-02-29 | $35.51M derived: sum of 3 quarters · filed 2016-02-29 | $45.05M 10-K · filed 2016-02-29 | $95.51M 10-K · filed 2014-03-03 | |||||||||||||||
| 2013-09-30 | $12.07M 10-Q · filed 2014-11-10 | $22.51M derived: sum of 2 quarters · filed 2014-11-10 | $32.04M 10-Q · filed 2014-11-10 | $40.32M derived: sum of 4 quarters · filed 2015-03-02 | $82.50M 10-Q · filed 2013-11-12 | |||||||||||||||
| 2013-06-30 | $10.44M 10-Q · filed 2014-08-11 | $19.97M 10-Q · filed 2014-08-11 | $28.25M derived: sum of 3 quarters · filed 2015-03-02 | $46.03M derived: sum of 4 quarters · filed 2015-03-02 | $70.43M 10-Q · filed 2013-08-06 | |||||||||||||||
| 2013-03-31 | $9.53M 10-Q · filed 2014-05-12 | $17.81M derived: sum of 2 quarters · filed 2015-03-02 | $35.59M derived: sum of 3 quarters · filed 2015-03-02 | $48.60M derived: sum of 4 quarters · filed 2015-03-02 | $59.99M 10-Q · filed 2013-05-09 | |||||||||||||||
| 2012-12-31 | $8.28M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $26.06M derived: sum of 2 quarters · filed 2015-03-02 | $39.07M derived: sum of 3 quarters · filed 2015-03-02 | $49.64M 10-K · filed 2015-03-02 | $50.46M 10-K · filed 2013-04-01 | |||||||||||||||
| 2012-09-30 | $17.78M 10-Q · filed 2013-11-12 | $17.78M 10-Q · filed 2012-11-14 | $30.79M derived: sum of 2 quarters · filed 2013-11-12 | $41.35M 10-Q · filed 2013-11-12 | $41.35M 10-Q · filed 2012-11-14 | $42.18M 10-Q · filed 2012-11-14 | ||||||||||||||
| 2012-06-30 | $13.01M 10-Q · filed 2013-08-06 | $13.01M 10-Q · filed 2012-08-14 | $23.57M 10-Q · filed 2013-08-06 | $23.57M 10-Q · filed 2012-08-14 | $24.40M 10-Q · filed 2012-08-14 | |||||||||||||||
| 2012-03-31 | $10.57M 10-Q · filed 2013-05-09 | $10.57M 10-Q · filed 2012-05-15 | $11.39M 10-Q · filed 2012-05-15 | |||||||||||||||||
| 2011-12-31 | $826.00K 10-K · filed 2014-03-03 | $826.37K 10-K · filed 2012-03-29 | $826.37K 10-K · filed 2012-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |